Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - September 2017

Recent News

Sep. 26, 2017Juno Therapeutics Closes Follow-on Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesPrinter Friendly Version
Sep. 21, 2017Juno Therapeutics Prices $250 Million Follow-on OfferingPrinter Friendly Version
Sep. 21, 2017Juno Therapeutics Opens New Headquarters and Research CenterPrinter Friendly Version
Sep. 20, 2017Juno Therapeutics Launches Follow-on OfferingPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Past Events

There are no past events to display.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
JUNO (Common Stock)
Change Stock is Down 0.48 (1.11%)
Data as of Oct. 19, 2017 11:47 a.m. ET